{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T15:12:42Z","timestamp":1781881962480,"version":"3.54.5"},"reference-count":27,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2016,2,5]],"date-time":"2016-02-05T00:00:00Z","timestamp":1454630400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"name":"Experimental Cancer Medicine Centre Funding"},{"DOI":"10.13039\/100010417","name":"University Hospital Southampton NHS Foundation Trust","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100010417","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Br J Haematol"],"published-print":{"date-parts":[[2016,4]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p>We report a phase <jats:styled-content style=\"fixed-case\">II<\/jats:styled-content> study to evaluate the efficacy and toxicity of abbreviated immunochemotherapy followed by\u00a0<jats:sup>90<\/jats:sup>Y Ibritumomab tiuxetan (<jats:sup>90<\/jats:sup>Y\u2010<jats:styled-content style=\"fixed-case\">IT<\/jats:styled-content>) in patients with recurrent follicular lymphoma. Of the 52 patients enrolled, 50 were treated with three cycles of R\u2010<jats:styled-content style=\"fixed-case\">CHOP<\/jats:styled-content> (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisolone) or R\u2010<jats:styled-content style=\"fixed-case\">CVP<\/jats:styled-content> (rituximab, cyclophosphamide, vincristine, prednisolone), followed by\u00a0<jats:sup>90<\/jats:sup>Y\u2010<jats:styled-content style=\"fixed-case\">IT<\/jats:styled-content> regimen (15 <jats:styled-content style=\"fixed-case\">MB<\/jats:styled-content>q\/kg, maximum 1200 <jats:styled-content style=\"fixed-case\">MB<\/jats:styled-content>q) preceded by two infusions of 250\u00a0mg\/m<jats:sup>2<\/jats:sup> rituximab. The overall response rate was 98%\u00a0with complete response (<jats:styled-content style=\"fixed-case\">CR<\/jats:styled-content>) 30% and partial response (<jats:styled-content style=\"fixed-case\">PR<\/jats:styled-content>) 68%. 18 patients with a <jats:styled-content style=\"fixed-case\">PR<\/jats:styled-content> following chemotherapy improved to a <jats:styled-content style=\"fixed-case\">CR<\/jats:styled-content> following\u00a0<jats:sup>90<\/jats:sup>Y\u2010<jats:styled-content style=\"fixed-case\">IT<\/jats:styled-content>: a conversion rate of 40%.\u00a0Seven patients with <jats:styled-content style=\"fixed-case\">PR<\/jats:styled-content> following\u00a0<jats:sup>90<\/jats:sup>Y\u2010<jats:styled-content style=\"fixed-case\">IT<\/jats:styled-content> subsequently improved to a <jats:styled-content style=\"fixed-case\">CR<\/jats:styled-content> 12\u201318\u00a0months later, leading to an overall <jats:styled-content style=\"fixed-case\">CR<\/jats:styled-content> rate of 44%. With a median follow\u2010up of 5\u00a0years, median progression\u2010free survival was 23\u00b71\u00a0months and overall survival was 77\u00b75% at 5\u00a0years. High trough serum rituximab levels (median 112\u00a0\u03bcg\/ml; range 52\u2013241) were attained after four doses of rituximab, prior to\u00a0<jats:sup>90<\/jats:sup>Y\u2010<jats:styled-content style=\"fixed-case\">IT<\/jats:styled-content>; this was not found to influence response rates. The treatment was well tolerated with few (13\u00b75%) grade 3 or 4 infective episodes and manageable haematological toxicity. Abbreviated immunochemotherapy followed by\u00a0<jats:sup>90<\/jats:sup>Y\u2010<jats:styled-content style=\"fixed-case\">IT<\/jats:styled-content> is an effective and well\u2010tolerated treatment in recurrent follicular lymphoma patients previously exposed to rituximab. Trial registration: clinicaltrials.gov identifier: NCT00637832.<\/jats:p>","DOI":"10.1111\/bjh.13954","type":"journal-article","created":{"date-parts":[[2016,2,5]],"date-time":"2016-02-05T12:17:29Z","timestamp":1454674649000},"page":"274-282","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Short duration immunochemotherapy followed by radioimmunotherapy consolidation is effective and well tolerated in relapsed follicular lymphoma: 5\u2010year results from a <scp>UK<\/scp> National Cancer Research Institute Lymphoma Group study"],"prefix":"10.1111","volume":"173","author":[{"given":"Tim M.","family":"Illidge","sequence":"first","affiliation":[{"name":"Manchester Academic Health Sciences Centre University of Manchester Christie NHS Foundation Trust Manchester UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hayley S.","family":"McKenzie","sequence":"additional","affiliation":[{"name":"NIHR\/Cancer Research UK Experimental Cancer Medicine Centre Southampton UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sam","family":"Mayes","sequence":"additional","affiliation":[{"name":"Manchester Academic Health Sciences Centre University of Manchester Christie NHS Foundation Trust Manchester UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Bates","sequence":"additional","affiliation":[{"name":"NIHR\/Cancer Research UK Experimental Cancer Medicine Centre Southampton UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew J.","family":"Davies","sequence":"additional","affiliation":[{"name":"NIHR\/Cancer Research UK Experimental Cancer Medicine Centre Southampton UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruth","family":"Pettengell","sequence":"additional","affiliation":[{"name":"Department of Haematology St Georges University of London London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louise","family":"Stanton","sequence":"additional","affiliation":[{"name":"Southampton Clinical Trials Unit Southampton UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelly","family":"Cozens","sequence":"additional","affiliation":[{"name":"Southampton Clinical Trials Unit Southampton UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grace","family":"Hampson","sequence":"additional","affiliation":[{"name":"Clinical and Experimental Pharmacology Group Cancer Research UK Manchester Institute The University of Manchester Manchester UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Dive","sequence":"additional","affiliation":[{"name":"Clinical and Experimental Pharmacology Group Cancer Research UK Manchester Institute The University of Manchester Manchester UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maureen","family":"Zivanovic","sequence":"additional","affiliation":[{"name":"Manchester Academic Health Sciences Centre University of Manchester Christie NHS Foundation Trust Manchester UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jill","family":"Tipping","sequence":"additional","affiliation":[{"name":"Manchester Academic Health Sciences Centre University of Manchester Christie NHS Foundation Trust Manchester UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eve","family":"Gallop\u2010Evans","sequence":"additional","affiliation":[{"name":"Clinical Trials Unit Velindre Cancer Centre Cardiff UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John A.","family":"Radford","sequence":"additional","affiliation":[{"name":"Manchester Academic Health Sciences Centre University of Manchester Christie NHS Foundation Trust Manchester UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter W.M.","family":"Johnson","sequence":"additional","affiliation":[{"name":"NIHR\/Cancer Research UK Experimental Cancer Medicine Centre Southampton UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2016,2,5]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.4065\/80.8.1087"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1997.15.3.1110"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.4.1244"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.2147\/CMR.S6765"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428190500376076"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2004.00.9217"},{"key":"e_1_2_7_8_1","first-page":"176","article-title":"The role of complement in the therapeutic activity of rituximab in a murine B lymphoma model homing in lymph nodes","volume":"91","author":"Golay J.","year":"2006","journal-title":"Haematologica"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1314583"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.3816\/CLM.2004.n.015"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.3816\/CLM.2009.n.044"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jim.2010.05.009"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.beha.2011.03.005"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-08-175653"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-08-0529"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.24714"},{"key":"e_1_2_7_17_1","first-page":"369","article-title":"A randomized phase II study comparing consolidation with a single dose of 90y Ibritumomab Tiuxetan (Zevalin\u00ae) (Z) vs. maintenance with Rituximab (R) for two years in patients with newly diagnosed follicular lymphoma (FL) responding to R\u2010CHOP. preliminary results at 36\u00a0months from randomization","volume":"122","author":"Lopez\u2010Guillermo A.","year":"2013","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.canep.2011.08.006"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.41.1553"},{"key":"e_1_2_7_20_1","doi-asserted-by":"crossref","first-page":"3909","DOI":"10.1182\/blood.V89.11.3909","article-title":"A clinical evaluation of the International Lymphoma Study Group classification of non\u2010Hodgkin's lymphoma The Non\u2010Hodgkin's Lymphoma Classification Project","volume":"89","author":"The Non\u2010Hodgkin's Lymphoma Classification Project","year":"1997","journal-title":"Blood"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1089\/cbr.2005.20.185"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V99.12.4336"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.12.3793"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2002.11.017"},{"key":"e_1_2_7_25_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2002.11.076"},{"key":"e_1_2_7_26_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.22617"},{"key":"e_1_2_7_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(08)70039-1"},{"key":"e_1_2_7_28_1","doi-asserted-by":"publisher","DOI":"10.3816\/CLML.2010.n.054"}],"container-title":["British Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fbjh.13954","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bjh.13954","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,3]],"date-time":"2023-10-03T00:26:24Z","timestamp":1696292784000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/bjh.13954"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,2,5]]},"references-count":27,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2016,4]]}},"alternative-id":["10.1111\/bjh.13954"],"URL":"https:\/\/doi.org\/10.1111\/bjh.13954","archive":["Portico"],"relation":{},"ISSN":["0007-1048","1365-2141"],"issn-type":[{"value":"0007-1048","type":"print"},{"value":"1365-2141","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,2,5]]},"assertion":[{"value":"2015-10-20","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2015-11-30","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2016-02-05","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}